Skip to main content
. 2018 Feb 20;41(5):2517–2526. doi: 10.3892/ijmm.2018.3506

Figure 8.

Figure 8

Effects of BMP2 overexpression on Dex-induced protein alterations in MC3T3-E1 cells. MC3T3-E1 cells were infected with pLVX-BMP2 prior to 1 µM Dex treatment for 48 h, in the absence or presence of 60 µM mangiferin pretreatment for 3 h. (A) Cell lysates were subjected to western blot analysis using BMP2, p-Smad-1 and Smad-1-specific antibodies. (B) Intensity of the protein bands of a typical experiment was semi-quantified using ImageJ 1.41o software. (C) Cell lysates were subjected to western blot analysis using OSX, OCN, OPG, RANK, RANKL, Bcl-2, and Bax-specific antibodies. (D and E) Intensity of the protein bands of a typical experiment was semi-quantified using ImageJ 1.41o software. +++P<0.001 compared with the control group; #P<0.05, ##P<0.01 and ###P<0.001 compared with the Dex treatment group; &P<0.01 and &&P<0.01 compared with the Dex + pLVX-BMP2 treatment group. Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2; BMP2, bone morphogenetic protein 2; Dex, dexamethasone; OCN, osteocalcin; OPG, osteoprotegerin; OSX, osterix; p-Smad-1, phosphorylated-Smad-1; t-Smad-1, total Smad-1; RANK, receptor activator of nuclear factor-κB; RANKL, RANK ligand; Smad-1, SMAD family member 1.